Abstract
Alzheimer's disease is the most common form of dementia, affecting 26 million people worldwide. The Aβ peptide (39-43 amino acids) derived from the proteolytic cleavage of the amyloid precursor protein is one of the main constituents of amyloid plaques associated with disease pathogenesis and therefore a validated target for therapy. Recently, we characterized antibody fragments (Fab and scFvs) derived from the murine monoclonal antibody WO-2, which bind the immunodominant epitope (3EFRH6) in the Aβ peptide at the N-terminus. In vitro, these fragments are able to inhibit fibril formation, disaggregate preformed amyloid fibrils, and protect neuroblastoma cells against oligomer-mediated toxicity. In this study, we describe the humanization of WO-2 using complementary determining region loop grafting onto the human germline gene and the determination of the three-dimensional structure by X-ray crystallography. This humanized version retains a high affinity for the Aβ peptide and therefore is a potential candidate for passive immunotherapy of Alzheimer's disease. © 2009 The Protein Society.
Author supplied keywords
Cite
CITATION STYLE
Robert, R., Streltsov, V. A., Newman, J., Pearce, L. A., Wark, K. L., & Dolezal, O. (2010). Germline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragment. Protein Science, 19(2), 299–308. https://doi.org/10.1002/pro.312
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.